New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
07:02 EDTISISIsis Pharmaceuticals receives $15M milestone payment from AstraZeneca
Isis Pharmaceuticals announced that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR in patients with cancer. Isis earned a $15M milestone payment associated with the clinical advancement of ISIS-AR. ISIS-AR is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor. AstraZeneca is planning to develop ISIS-AR broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
07:05 EDTISISAkcea Therapeutica receives orphan drug designatoin from FDA for Volanesorsen
Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, announced that the FDA has granted Orphan Drug Designation to volanesorsen for the treatment of patients with Familial Chylomicronemia Syndrome. FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis. In a Phase 2 study published in the NEJM in December 2014, patients with FCS treated with volanesorsen achieved substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol particles.1 Akcea is currently conducting an international multi-center, randomized, double-blind, placebo-controlled Phase 3 study in patients with FCS.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
June 22, 2015
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use